Another $500,000 Pledge to Type 2 Research!
Bruce Chizen, a special advisor to the Board of Directors, will match donations to CMT2 research on a one-to-one basis, up to $500,000.
Read more ... The 2019 Fall CMTA Report
The Type 2 Issue: We have set the stage for a number of Type 2 breakthroughs on our way to treatments for CMT.
Read more ... New Gene Therapy, Type 1/Type 4 Research Projects Approved
The CMTA today announced another $335,000 in grants to top CMT scientists leading the field in CMT Type 1 research. The grants cover work on types 1A, 1B and 1X and other demyelinating forms of CMT, including type 4.
Read more ... New Gene Therapy Development Program for CMT2A
Passage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).
Read more ... $1 Million Gift Pledged to CMT Type 2 Research!
Bob and Gail Buuck are big believers in “impact giving,” They have pledged a $1 million gift to advance CMT Type 2 research.
Read more ...